Related Experiment Video
Updated: Jul 17, 2026
07:56
Utilizing Time-Resolved Protein-Induced Fluorescence Enhancement to Identify Stable Local Conformations One α-Synuclein Monomer at a Time
Published on: May 30, 2021
Observation of multiple intermediates in alpha-synuclein fibril formation by singular value decomposition analysis
Tomoaki Kamiyoshihara1, Masaki Kojima, Kenji Uéda
1School of Life Science, Tokyo University of Pharmacy and Life Science, Horinouchi, Hachioji, Tokyo 192-0392, Japan.
Biochemical and Biophysical Research Communications
|February 16, 2007
Summary
Parkinson's disease involves alpha-synuclein polymerization. This study used spectroscopy and SVD analysis to reveal multiple intermediates in wild-type alpha-synuclein fibril formation, offering insights into disease mechanisms.
Area of Science:
- Neuroscience
- Biochemistry
- Structural Biology
Background:
- Parkinson's disease (PD) is characterized by alpha-synuclein protein aggregation into fibrils, forming Lewy bodies.
- The precise molecular mechanisms underlying alpha-synuclein aggregation and fibrillation remain incompletely understood.
Purpose of the Study:
- To investigate the structural properties and fibril formation propensities of wild-type and mutant alpha-synuclein variants (A30P, E46K, A53T).
- To elucidate the multi-step process and identify intermediates in alpha-synuclein fibrillation.
Main Methods:
- Utilized fluorescence and circular dichroism (CD) spectroscopy to monitor protein structural changes.
- Applied singular value decomposition (SVD) analysis to time-dependent CD spectra for identifying conformational species.
Main Results:
- Wild-type alpha-synuclein fibrillation was confirmed as a multi-step process.
- SVD analysis indicated the formation of five to nine distinct intermediates during the early stages of fibrillation.
Conclusions:
- The study provides a detailed mechanistic insight into alpha-synuclein fibril formation.
- Understanding these intermediates is crucial for developing therapeutic strategies targeting Parkinson's disease progression.
